Trial | NCT01080846  Report issue

Title

Fever After Misoprostol Administration for the Treatment of Primary Postpartum Hemorrhage
Assessment of Fever After Misoprostol Administration for the Treatment of Primary Postpartum Hemorrhage

  • Phase

    N/A

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    50
This study will evaluate side effects after sublingual misoprostol (600 mcg) as a first-line treatment for primary postpartum hemorrhage (PPH) due to suspected uterine atony.
The study purpose is to confirm whether a lower, 600 mcg dose of sublingual misoprostol will reduce the incidence of elevated body temperature (≥40°C) associated with misoprostol. The study will compare the incidence of high fevers following treatment with 600 mcg sublingual misoprostol to previously documented rates using 800 mcg sublingual misoprostol. An additional line of research is to investigate whether some women are more susceptible to experiencing high fevers following misoprostol administration, and whether genetic factors are responsible for misoprostol-induced fevers.
Study Started
Feb 28
2010
Primary Completion
Aug 31
2010
Study Completion
Aug 31
2010
Last Update
Nov 11
2010
Estimate

Drug Misoprostol

600 mcg of sublingual misoprostol

600 mcg of sublingual misoprostol Experimental

Criteria 

Inclusion Criteria:

Able and willing to give informed consent
Vaginal delivery
Postpartum hemorrhage due to suspected uterine atony
Oxytocin given during 3rd stage of labor

Exclusion Criteria:

Known allergy to prostaglandins or misoprostol
Underwent cesarean section
Postpartum hemorrhage NOT due to suspected uterine atony
Oxytocin NOT given during 3rd stage of labor
Severe ill health
Unable to give informed consent
No Results Posted